These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

623 related items for PubMed ID: 15115831

  • 1. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
    Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR, AIDS Clinical Trials Group Study A5095 Team.
    N Engl J Med; 2004 Apr 29; 350(18):1850-61. PubMed ID: 15115831
    [Abstract] [Full Text] [Related]

  • 2. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM.
    N Engl J Med; 1999 Dec 16; 341(25):1865-73. PubMed ID: 10601505
    [Abstract] [Full Text] [Related]

  • 3. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
    Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA, AIDS Clinical Trials Group 364 Study Team.
    N Engl J Med; 2001 Aug 09; 345(6):398-407. PubMed ID: 11496850
    [Abstract] [Full Text] [Related]

  • 4. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
    DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, Brothers CH, Hernandez J, Castillo SA, Bonny T, Lanier ER, Scott TR, CNA30024 Study Team.
    Clin Infect Dis; 2004 Oct 01; 39(7):1038-46. PubMed ID: 15472858
    [Abstract] [Full Text] [Related]

  • 5. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
    Ruane PJ, Parenti DM, Margolis DM, Shepp DH, Babinchak TJ, Van Kempen AS, Kauf TL, Danehower SA, Yau L, Hessenthaler SM, Goodwin D, Hernandez JE, COL30336 Study Team.
    HIV Clin Trials; 2003 Oct 01; 4(4):231-43. PubMed ID: 12916008
    [Abstract] [Full Text] [Related]

  • 6. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults.
    Pérez-Elías MJ, Moreno A, Moreno S, López D, Antela A, Casado JL, Dronda F, Gutiérrez C, Quereda C, Navas E, Abraira V, Rodríguez MA.
    HIV Clin Trials; 2005 Oct 01; 6(6):312-9. PubMed ID: 16452065
    [Abstract] [Full Text] [Related]

  • 7. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L, Pugliese P, Bugnon F, Delpierre C, Cua E, Billaud E, Massip P, Raffi F, Dellamonica P.
    HIV Med; 2005 Nov 01; 6(6):388-95. PubMed ID: 16268820
    [Abstract] [Full Text] [Related]

  • 8. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
    Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM, Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team.
    N Engl J Med; 2003 Sep 11; 349(11):1036-46. PubMed ID: 12968087
    [Abstract] [Full Text] [Related]

  • 9. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P, Lang J, DeJesus E, Berger DS, Dretler R, Rodriguez A, Ward DJ, Lim ML, Liao Q, Reddy S, Clair MS, Vila T, Shaefer MS.
    HIV Clin Trials; 2006 Sep 11; 7(5):229-36. PubMed ID: 17162316
    [Abstract] [Full Text] [Related]

  • 10. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
    Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR.
    AIDS; 2007 Apr 23; 21(7):813-23. PubMed ID: 17415036
    [Abstract] [Full Text] [Related]

  • 11. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
    Matheron S, Descamps D, Boué F, Livrozet JM, Lafeuillade A, Aquilina C, Troisvallets D, Goetschel A, Brun-Vezinet F, Mamet JP, Thiaux C, CNA3007 Study Group.
    Antivir Ther; 2003 Apr 23; 8(2):163-71. PubMed ID: 12741629
    [Abstract] [Full Text] [Related]

  • 12. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK, Study 934 Group.
    N Engl J Med; 2006 Jan 19; 354(3):251-60. PubMed ID: 16421366
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W, CNAAB3005 International Study Team.
    JAMA; 2001 Mar 07; 285(9):1155-63. PubMed ID: 11231744
    [Abstract] [Full Text] [Related]

  • 15. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.
    Cochrane Database Syst Rev; 2013 Jun 05; 2013(6):CD008270. PubMed ID: 23740608
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
    Henry K, Wallace RJ, Bellman PC, Norris D, Fisher RL, Ross LL, Liao Q, Shaefer MS, TARGET Study Team.
    J Infect Dis; 2001 Feb 15; 183(4):571-8. PubMed ID: 11170982
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
    Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M, McNamara J, Mofenson LM, Purdue L, Siminski S, Graham B, Kornhauser DM, Fiske W, Vincent C, Lischner HW, Dankner WM, Flynn PM.
    N Engl J Med; 1999 Dec 16; 341(25):1874-81. PubMed ID: 10601506
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.